September 5, 2025JAMA
Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults
Authors
Discussion
Loading...
Member takes
Implication
Secondary analysis evaluates RSVpreF vaccine's impact on cardiovascular outcomes in older adults, indicating potential benefits.
Key Points
- All-cause cardiorespiratory hospitalization was significantly lower in the RSVpreF group than control, suggesting efficacy.
- Vaccine effectiveness for cardiorespiratory hospitalization was 9.9%, indicating potential benefits from RSV immunization.
- The study involved a pragmatic, open-label, individually randomized trial in Denmark with over 131,000 participants.
- Findings highlight the need for further investigation, as cardiovascular hospitalization results were not statistically significant.
Cite This Study
Lassen et al. (2025) studied this question.